Jona Hattangadi-Gluth, MD

🚨🚨Brain RT can affect fine motor skills (FMS) ✍️📱 & 🖐️👁️coordination. But can we PREVENT it? YES! ➡️Check out our lab’s latest from 🔥Dr. Mike Connor: 1st NTCP study of FMS using multivariate approach & prospective data #btsm #survivorship #functionalpreservation 1/🧵

Congrats to Moores Member Catheryn Yashar, MD, for receiving the ACRO Gold Medal! Honored by the ACRO Board of Chancellors, she’s recognized for her outstanding service and exceptional contributions to radiation oncology. Learn more: bit.ly/44RoHG4

@BobCarterMD @theNAMedicine @ArlottaLab @StanfordMed Congratulations Bob! Well deserved !

I was happy to share the excitement of being inducted today into the National Academy of Medicine @theNAMedicine with fellow class of 2024 members Paola Arlotta (noted stem cell biologist @ArlottaLab) and Tina Stankovic (chair of ENT @StanfordMed), and neurosurgeons Robert Martuza (a great mentor and sponsor from @MGBneurosurgery) and Robert Friedlander (friend and chair of Neurosurgery @PittNeurosurg). We shared memories of our early days together @MGHNeurosurg and the varied and unique scientific journeys that brought us to the National Academy of Medicine. A special day for me to be with these friends, and congrats to all those inducted today!

🚨TOROEDO trial - superbly executed with uniform RT plan QA/no crossover. No difference in either endpoints. What’s next? Refine the strategy. Technology is a means to an end. Reduce volume and dose (gross/elective) with biology based therapy selection. @ASTRO_org #astro25

@Dr_RShatsky @DFCI_BreastOnc @nyugrossman @Perlmutter_CC Absolutely a team effort, learning from Dr. Yang-whose work has transformed the field-& how to bring this to our patients. We need great partners like @Dr_RShatsky who fiercely advocate for earlier detection & novel therapies #lmd

@DFCI_BreastOnc @nyugrossman @Perlmutter_CC Expert CNS radiation oncologist Dr Jona Hattangadi has been instrumental in the development in much of this work. She deserves recognition here. @JHGLab

Jonathan Yang, MD, PhD, Associate Professor in Radiation Oncology @nyugrossman and Co-Director of Brain and Spine Tumor Center at @Perlmutter_CC discussed the evolving role of #RadiationTherapy for #LeptomeningealMetastases in our #CentralNervousSystem Metastases Seminar Series. #CNS #BrainMetastases #MBC #BCBM @nlinmd @drsarahsam @AyalAizer @RMJesel

@marklewismd 😂😂😂

The stomach and kidneys preparing for the onslaught of NSAIDs

@Dr_RShatsky Amen!!!

There is truly an explosion in leptomeningeal disease in cancer right now and we need better education in all aspects of medicine on early diagnosis and urgency of treatment. We’ve gotten better at treating the body, but now it’s time to focus on the CNS #Leptomeningeal #braincancer #CNS This requires TRUE multidisciplinary care! @nlinmd @drsarahsam

@Dr_RShatsky @nlinmd @NeuroOnc @DrJNaidoo @UCSDCancer 🥹Thank you! This trial has been my blood, sweat and tears for the past 7 years. So excited to share our results and bring this innovation to more patients #survivorship #functionalsparing

@nlinmd @JHGLab @NeuroOnc @DrJNaidoo That’s my gal!! Yay @JHGLab !!!! She’s the best! @UCSDCancer

Groundbreaking presentation from @JHGLab - NIH-funded trial of Brain connectome-sparing SRS w/ AI-supported planning approaches is: -feasible -assoc with good tumor control and stable/improved cognitive function -time for a randomized trial! @NeuroOnc

@NiuSanford One of my absolutely most favorite people 😊

Look who I found at the Brigham! Harvey Mamon is one of the most thoughtful rad oncs I know. Excited to see him as co-chair of the NCI GI steering committing starting this Fall.

@joshuapalmermd @MyrsiniIoakeim @MGHCancerCenter Thanks Josh! Excited to hear about your work next month at SNO/ASCO

@JHGLab @MyrsiniIoakeim @MGHCancerCenter Amazing data, pushing the field forward. Your work led us to try memory avoidance WBRT. Can’t wait to see what comes next!

Incredible #RadOnc Grand Rounds @MGHCancerCenter by Dr. Jona Hattangadi-Gluth @JHGLab on oncofunctional balance in brain tumors—from connectomics to clinical trials. Loved the focus on neuroimaging biomarkers, cognitive-sparing therapies, and the future of precision radiation medicine. 📸: Slides from her COG-SRS and MIND trial @UCSDRadMed #NeuroOncology #BrainTumors #PrecisionMedicine

Congratulation to all awardees🎉🥳, especially our own Helen Shih who we are so lucky to have amongst us. Dr Shih's passion for mentoring and excellence is absolutely amazing, and she does it all with the highest level of diligence & integrity. An inspiration to all of us‼️ 👏👏👏 @MGHCancerCenter @MGH_WiO @BrighamRadOnc @DKirschMDPhD @AmyWisdom8 @RachelJimenezMD @AE_MarciscanoMD @EmilyLebow

@EvanThomas84 This is all so frightening. People’s entire careers and research portfolios upended and destroyed.

If you’re in medicine and this doesn’t immediately make your gut turn, you probably don’t belong in medicine.

@seanmmcbride Well he isn’t wrong 😑

He’s asking to replace EPIC with this.

<son rummaging through my iphone with full storage so he can find apps to delete and install a game> Son: Dada! Can I delete EPIC? Me: Son: Can I? Me: Um.... ............@blandro #medwtitter #radonc

@seanmmcbride @SarahEMcBride @blandro Amazing! Congratulations

So proud :) @SarahEMcBride @blandro

@PDBrownOnc Sounds like a win to me!! Your expertise is and always will be so valuable, and 80 percent is crazy high. More time for grand baby snuggles and gardening 😉

Fired from editorial board Don’t blame them-I only review manuscripts that interest me and want to read, which is about 20%

⁦@Paddy_lax⁩ rang the bell! Radiation ✅ done. Gratitude for the terrific team ⁦@UCSDHealth⁩ under ⁦@JHGLab⁩ 😍🥹🙏🏻

@anneod7 @Paddy_lax @UCSDHealth Go Paddy!! We are so proud of him and his amazing family and community of friends 🏒@UCSDCancer @UCSDRadMed

@TylerSbrt @PDBrownOnc Interesting! Yes, I remember highlighting this at ASTRO in abstract form. Both arms vols/margins are large. And no real diff. Better cognitive sparing, tracking of infiltrating dz w/ novel imaging➡️ I hope that’s the future of trials. Need smarter targeting, not bigger margins

@PDBrownOnc @JHGLab Agreed. Still a nice study—no difference in PFS or OS is interesting. But when paired with no difference in toxicity, could conclude it doesn’t matter which volumes you use. Possibly true, of course. I favor smaller volumes until I see a larger trial 🙂

No difference in toxicity strikes me as a reflection of our poor routine measurement of 🧠 changes @JHGLab @PDBrownOnc I can’t see the full text right now. Were treatment volumes (mL) v different? redjournal.org/article/S0360-…

NIH funding generated $2.46 for every $1 funded in 2023. Important info for scientific advocacy in the years ahead- science is a quantifiable investment, not just a cost. H/t to @NicoleCRust for sharing! fiercebiotech.com/research/repor…